BPC-157 half-life and pharmacokinetics chart
Pre-filled plasma half-life model for BPC-157. See how a 4 hours half-life affects steady state, accumulation, peak-trough swing, and clearance timing.
Preset values: 250 mcg every 1 day, half-life ~4 hours.
Estimated ~4h subq half-life. Many users split into 2× daily doses to maintain tissue exposure.
Open interactive chart →Why these values?
The half-life used here (4 hours) is the published or well-established estimate for BPC-157 from pharmacokinetic studies. The default dose (250 mcg) and cadence (every 1 day) reflect typical standard protocols — not a prescription or recommendation. Your specific product's label and your clinician's protocol override any default here.
Accumulation. With a half-life of 4 hours and dosing every 1 day, the ratio τ/t½ = 6.00 gives an accumulation factor of ~1.02×. That means the steady-state peak plasma mass is about 1.0× the mass of a single dose.
Time to steady state. Approximately 5 half-lives (~0.8 days) of consistent dosing before average concentration stops rising. Dose-escalation protocols that change doses before this point are titrating against a still-rising baseline, which is one reason weekly peptides feel "slow" at the start.
What the chart shows — and what it doesn't
The visualizer is a simple first-order single-compartment exponential decay model. It's accurate enough for understanding dosing rhythm, peak-trough ratios, and steady-state math, but not clinical pharmacokinetics. It doesn't model:
- Absorption delay from subcutaneous injection depots
- Two-compartment distribution (central vs peripheral)
- Protein binding (significant for GLP-1 agonists with albumin binding)
- Individual variability in clearance (renal, hepatic)
- Receptor-level effects that outlast plasma clearance
For most questions about "how often should I dose," the model is sufficient. For clinical decisions, use the manufacturer's label and a qualified prescriber.
BPC-157 half-life FAQ
What is the plasma half-life of BPC-157?
This chart uses an estimated BPC-157 plasma half-life of about 4 hours. Published values can vary by formulation, route, assay, and study design.
How long until BPC-157 reaches steady state?
A simple first-order model reaches practical steady state after about five half-lives, which is roughly 20 hours for BPC-157.
Does this BPC-157 pharmacokinetics chart recommend a dosing schedule?
No. It visualizes half-life, accumulation, peaks, and troughs from values you enter. It is not a prescription, dose recommendation, or substitute for the product label or clinician guidance.
Why does steady state matter for BPC-157?
Steady state explains why long-half-life compounds can keep rising for weeks after starting or changing a dose, while short-half-life compounds behave more like brief pulses.
Related for BPC-157
Track your real BPC-157 protocol
Peptide Protocol logs every actual injection time and shows your real timeline — not a model. Side-effect tracking included.
Get the iPhone app →Educational use only. Nothing on this page constitutes medical advice. Pharmacokinetic parameters are published estimates; individual PK varies. Use label values and consult a clinician for any dosing decision.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.